Literature DB >> 11849548

Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C-terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer.

Angela R Melton-Celsa1, John F Kokai-Kun, Alison D O'Brien.   

Abstract

Shiga toxins (Stx) are potent ribosome-inactivating toxins that are produced by Shigella dysenteriae type 1 or certain strains of Escherichia coli. These toxins are composed of one A subunit that can be nicked and reduced to an enzymatically active A1(approximately 27 kDa) and an A2 peptide (approximately 4 kDa) as well as a pentamer of B subunits (approximately 7 kDa/monomer) that binds the eukaryotic cell. Purified Shiga toxin type 2d is activated 10- to 1000-fold for Vero cell toxicity by preincubation with mouse or human intestinal mucus or purified mouse elastase, whereas Stx2, Stx2c, Stx2e and Stx1 are not activatable. E. coli strains that produce the activatable Stx2d are more virulent in a streptomycin (str)-treated mouse model of infection [lethal dose 50% (LD50) = 101] than are E. coli strains that produce any other type of Stx (LD50 = 1010). To identify the element(s) of Stx2d that are required for mucus-mediated activation, toxin genes were constructed such that the expressed mutant toxins consisted of hybrids of Stx2d and Stx1, Stx2 or Stx2e, contained deletions of up to six amino acids from the C-terminus of the A2 of Stx2d or were altered in one or both of the two amino acids of the A2 of Stx2d that represent the only amino acid differences between the activatable Stx2d and the non-activatable Stx2c. Analysis of these mutant toxins revealed that the A2 portion of Stx2d is required for toxin activation and that activation is abrogated if the Stx1 or Stx2e B subunit is substituted for the Stx2d B polypeptide. Furthermore, mass spectrometry performed on buffer- or elastase-treated Stx2d indicated that the A2 peptide of the activated Stx2d was two amino acids smaller than the A2 peptide from buffer-treated Stx2d. This finding, together with the toxin hybrid results, suggests that activation involves B pentamer-dependent cleavage by elastase of the C-terminal two amino acids from the Stx2d A2 peptide.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849548     DOI: 10.1046/j.1365-2958.2002.02733.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  31 in total

1.  A newly discovered verotoxin variant, VT2g, produced by bovine verocytotoxigenic Escherichia coli.

Authors:  P H M Leung; J S M Peiris; W W S Ng; R M Robins-Browne; K A Bettelheim; W C Yam
Journal:  Appl Environ Microbiol       Date:  2003-12       Impact factor: 4.792

2.  Presence of activatable Shiga toxin genotype (stx(2d)) in Shiga toxigenic Escherichia coli from livestock sources.

Authors:  Kari S Gobius; Glen M Higgs; Patricia M Desmarchelier
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

3.  Shiga-toxigenic Escherichia coli-inoculated neonatal piglets develop kidney lesions that are comparable to those in humans with hemolytic-uremic syndrome.

Authors:  J F Pohlenz; K R Winter; E A Dean-Nystrom
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Prevalences of Shiga toxin subtypes and selected other virulence factors among Shiga-toxigenic Escherichia coli strains isolated from fresh produce.

Authors:  Peter C H Feng; Shanker Reddy
Journal:  Appl Environ Microbiol       Date:  2013-08-30       Impact factor: 4.792

Review 5.  Induction of apoptosis by Shiga toxins.

Authors:  Vernon L Tesh
Journal:  Future Microbiol       Date:  2010-03       Impact factor: 3.165

Review 6.  Shiga Toxin (Stx) Classification, Structure, and Function.

Authors:  Angela R Melton-Celsa
Journal:  Microbiol Spectr       Date:  2014-08

7.  Top-down proteomic identification of Shiga toxin 2 subtypes from Shiga toxin-producing Escherichia coli by matrix-assisted laser desorption ionization-tandem time of flight mass spectrometry.

Authors:  Clifton K Fagerquist; William J Zaragoza; Omar Sultan; Nathan Woo; Beatriz Quiñones; Michael B Cooley; Robert E Mandrell
Journal:  Appl Environ Microbiol       Date:  2014-02-28       Impact factor: 4.792

8.  A novel murine infection model for Shiga toxin-producing Escherichia coli.

Authors:  Emily M Mallick; Megan E McBee; Vijay K Vanguri; Angela R Melton-Celsa; Katherine Schlieper; Brad J Karalius; Alison D O'Brien; Joan R Butterton; John M Leong; David B Schauer
Journal:  J Clin Invest       Date:  2012-10-08       Impact factor: 14.808

9.  Shiga toxin, cytolethal distending toxin, and hemolysin repertoires in clinical Escherichia coli O91 isolates.

Authors:  Martina Bielaszewska; Franziska Stoewe; Angelika Fruth; Wenlan Zhang; Rita Prager; Jens Brockmeyer; Alexander Mellmann; Helge Karch; Alexander W Friedrich
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

10.  Comparative pathogenicity of Escherichia coli O157 and intimin-negative non-O157 Shiga toxin-producing E coli strains in neonatal pigs.

Authors:  Evelyn A Dean-Nystrom; Angela R Melton-Celsa; Joachim F L Pohlenz; Harley W Moon; Alison D O'Brien
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.